Selma Metintas1,2, Guntulu Ak3,4, Emine Dundar1,5, Muzaffer Metintas1,6. 1. Eskisehir Osmangazi University Lung and Pleural Cancers Research and Clinical Center, Eskisehir, Turkey. 2. Medical Faculty Department of Public Health, Eskisehir Osmangazi University, Eskisehir, Turkey. 3. Eskisehir Osmangazi University Lung and Pleural Cancers Research and Clinical Center, Eskisehir, Turkey. guntuluak@gmail.com. 4. Medical Faculty Department of Chest Disease, Eskisehir Osmangazi University, 26000, Eskisehir, Turkey. guntuluak@gmail.com. 5. Medical Faculty Department of Pathology, Eskisehir Osmangazi University, Eskisehir, Turkey. 6. Medical Faculty Department of Chest Disease, Eskisehir Osmangazi University, 26000, Eskisehir, Turkey.
Abstract
OBJECTIVES: To investigate the changes in epidemiological and survival characteristics of malignant mesothelioma (MM) cases diagnosed in a 30-year period between 1990 and 2019. METHODS: Data were analyzed considering three time periods (1990-1999, 2000-2009, 2010-2019) when treatment practices changed. The Join point Regression Program was used to analyze the change in clinical and epidemiological characteristics of the cases. Kaplan-Meier analysis was used to calculate the overall survival of the patients. Cox regression analysis was used to determine the effect of variables on survival. RESULTS: The study group consisted of 928 MM patients. During the study period, the mean age of the patients and the percentage of epithelioid subtype increased, while the percentage of female and histopathologically unidentified cases decreased. The median survival (95%CI) of patients according to the study periods was 9.0 (7.2-10.9), 9.0 (7.6-10.4) and 12.0 (10.5-13.5) months, respectively. A significant increase in overall survival was observed in the time trend (p = 0.013). There was no significant change in overall survival in patients receiving best supportive care over the 30-year period (p = 0.060), but an improvement of 1.4 (95%CI 0.2 to 2.7) months (p = 0.027) was observed in patient receiving chemotherapy. An improvement in overall survival of 4.8 (1.2 to 8.4) months was also observed in patients receiving multimodality treatment during 2000-2019 (p = 0.014). MM patients who were younger, female, diagnosed after 2000, epithelioid subtype, early stage, and received chemotherapy or multimodal treatment had longer survival. CONCLUSIONS: It was found that histopathological diagnosis and treatment success in MM have improved over the years.
OBJECTIVES: To investigate the changes in epidemiological and survival characteristics of malignant mesothelioma (MM) cases diagnosed in a 30-year period between 1990 and 2019. METHODS: Data were analyzed considering three time periods (1990-1999, 2000-2009, 2010-2019) when treatment practices changed. The Join point Regression Program was used to analyze the change in clinical and epidemiological characteristics of the cases. Kaplan-Meier analysis was used to calculate the overall survival of the patients. Cox regression analysis was used to determine the effect of variables on survival. RESULTS: The study group consisted of 928 MM patients. During the study period, the mean age of the patients and the percentage of epithelioid subtype increased, while the percentage of female and histopathologically unidentified cases decreased. The median survival (95%CI) of patients according to the study periods was 9.0 (7.2-10.9), 9.0 (7.6-10.4) and 12.0 (10.5-13.5) months, respectively. A significant increase in overall survival was observed in the time trend (p = 0.013). There was no significant change in overall survival in patients receiving best supportive care over the 30-year period (p = 0.060), but an improvement of 1.4 (95%CI 0.2 to 2.7) months (p = 0.027) was observed in patient receiving chemotherapy. An improvement in overall survival of 4.8 (1.2 to 8.4) months was also observed in patients receiving multimodality treatment during 2000-2019 (p = 0.014). MM patients who were younger, female, diagnosed after 2000, epithelioid subtype, early stage, and received chemotherapy or multimodal treatment had longer survival. CONCLUSIONS: It was found that histopathological diagnosis and treatment success in MM have improved over the years.
Authors: Vanya Delgermaa; Ken Takahashi; Eun-Kee Park; Giang Vinh Le; Toshiyuki Hara; Tom Sorahan Journal: Bull World Health Organ Date: 2011-06-13 Impact factor: 9.408
Authors: Eunice Sirri; Joachim Kieschke; Claudia Vohmann; Alexander Katalinic; Alice Nennecke; Meike Ressing; Andrea Eberle; Bernd Holleczek; Lina Jansen; Hermann Brenner Journal: Int J Cancer Date: 2020-03-03 Impact factor: 7.396
Authors: Paul Baas; Melinda J Daumont; Laure Lacoin; John R Penrod; Robert Carroll; Sudhir Venkatesan; Harveen Ubhi; Alan Calleja; Michael Snee Journal: Lung Cancer Date: 2021-11-10 Impact factor: 5.705
Authors: Nicholas J Vogelzang; James J Rusthoven; James Symanowski; Claude Denham; E Kaukel; Pierre Ruffie; Ulrich Gatzemeier; Michael Boyer; Salih Emri; Christian Manegold; Clet Niyikiza; Paolo Paoletti Journal: J Clin Oncol Date: 2003-07-15 Impact factor: 44.544
Authors: Lee M Krug; Harvey I Pass; Valerie W Rusch; Hedy L Kindler; David J Sugarbaker; Kenneth E Rosenzweig; Raja Flores; Joseph S Friedberg; Katherine Pisters; Matthew Monberg; Coleman K Obasaju; Nicholas J Vogelzang Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544
Authors: Tom Treasure; Loic Lang-Lazdunski; David Waller; Judith M Bliss; Carol Tan; James Entwisle; Michael Snee; Mary O'Brien; Gill Thomas; Suresh Senan; Ken O'Byrne; Lucy S Kilburn; James Spicer; David Landau; John Edwards; Gill Coombes; Liz Darlison; Julian Peto Journal: Lancet Oncol Date: 2011-06-30 Impact factor: 41.316